Fed. Circ. Questions If Safer OxyContin Profits Came From IP

By Dani Kass · October 7, 2024, 9:39 PM EDT

An attorney for Purdue Pharma didn't seem to find much purchase at the Federal Circuit on Monday as he argued that the company's patents for abuse-deterrent OxyContin weren't obvious, claiming other...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Case Information

Case Title

Purdue Pharma L.P. v. Accord Healthcare, Inc.

Case Number

23-1953

Court

Appellate - Federal Circuit

Nature of Suit

835 Patent - (ANDA) (Fed. Qst.)

Date Filed

May 30, 2023

Featured Stories

Quick Growth, Stiff Competition Led To Everstream's Ch. 11 No Photo Available

Emlyn Cameron

Everstream, a provider of fiber networks to businesses, was pushed into Chapter 11 by burdensome debt, disappointing returns on an agg... (more story)

Titans Of The Plaintiffs Bar: Philippe & Jennifer Selendy No Photo Available

Yun Park

Philippe and Jennifer Selendy, who met as associates at Cravath Swaine & Moore LLP and married in 1997, each spent nearly three decade... (more story)

Under The Radar: Bankruptcy News You May Have Missed No Photo Available

Emlyn Cameron

A creditors committee objected to Party City's liquidator, Gordon Brothers, being classified as an estate professional entitled to fun... (more story)